Letter | Published:

Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum

Nature volume 296, pages 570572 (08 April 1982) | Download Citation

Subjects

Abstract

The ‘dopamine hypothesis’ of schizophrenia states that the illness is due to overactivity of dopamine mechanisms in the brain. This hypothesis is based on two facts: (1) drugs, such as amphetamine, that enhance dopaminergic neurotransmission in the brain, may occasionally provoke a schizophrenic psychosis; and (2) acute administration of neuroleptic drugs, which are used to treat schizophrenia and other psychotic illnesses, causes blockade of brain dopamine receptors and initiates a chain of compensatory events which attempt to overcome such an action. We have previously shown that administration of neuroleptic drugs to rats for up to 18 months produces unexpected effects1,2: after 6 months, all signs of blockade of dopamine receptors in the striatum have disappeared, and thereafter striatal dopamine receptors increase in number and become behaviourally supersensitive to administered dopamine agonists such as apomorphine. We now show that such chronic exposure to neuroleptics completely alters other characteristics of striatal dopamine receptors, and that in the intact animal, these changes are associated with spontaneous overactivity of striatal dopaminergic mechanisms. Unless other dopaminergic brain areas, for example in the mesolimbic or mesocortical regions, react differently from the striatum, the mode of action of neuroleptics, and the dopamine hypothesis of schizophrenia, may have to be reconsidered.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Nature 278, 59–61 (1979).

  2. 2.

    , & Eur. J. Pharmac. 57, 365–375 (1979).

  3. 3.

    J. Physiol., Lond. 208, 691–703 (1970).

  4. 4.

    , , & Brain Res. 102, 164–173 (1976).

  5. 5.

    & Res. Commun. chem. Path. Pharmac. 8, 13–28 (1974).

  6. 6.

    , , & Nature 249, 664–666 (1974).

  7. 7.

    , , & Brain Res. 55, 476–480 (1973).

  8. 8.

    , & J. Pharm. Pharmac. 26, 275–277 (1974).

  9. 9.

    , & Eur. J. Pharmac. 33, 345–351 (1975).

  10. 10.

    , , & Brain Res. 135, 255–263 (1977).

  11. 11.

    , & J. Pharmac. exp. Ther. 206, 677–686 (1978).

  12. 12.

    & Eur. J. Pharmac. 27, 46–58 (1974).

  13. 13.

    & J. Physiol., Lond. 79, 255–285 (1933).

  14. 14.

    & in Neuropathology: Methods and Diagnosis (ed. Tedeschi, C. G.) 665–690 (Little Brown, Boston, 1970).

  15. 15.

    & J. Physiol., Lond. 106, 8–17 (1947).

  16. 16.

    , & Biochem. Pharmac. 27, 307–316 (1978).

Download references

Author information

Affiliations

  1. University Department of Neurology, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London SE5 8AF, UK and Agricultural Research Council, Institute of Animal Physiology, Babraham, Cambridge CB2 4AT, UK

    • K. Murugaiah
    • , A. Theodorou
    • , S. Mann
    • , A. Clow
    • , P. Jenner
    •  & C. D. Marsden

Authors

  1. Search for K. Murugaiah in:

  2. Search for A. Theodorou in:

  3. Search for S. Mann in:

  4. Search for A. Clow in:

  5. Search for P. Jenner in:

  6. Search for C. D. Marsden in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/296570a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.